Pulmonary alveolar proteinosis - Archive ouverte HAL Access content directly
Journal Articles Respirology Year : 2020

Pulmonary alveolar proteinosis


PAP is an ultra-rare disease in which surfactant components, that impair gas exchange, accumulate in the alveolae. There are three types of PAP. The most frequent form, primary PAP, includes autoimmune PAP which accounts for over 90% of all PAP, defined by the presence of circulating anti-GM-CSF antibodies. Secondary PAP is mainly due to haematological disease, infections or inhaling toxic substances, while genetic PAP affects almost exclusively children. PAP is suspected if investigation for ILD reveals a crazy-paving pattern on chest CT scan, and is confirmed by a milky looking BAL that gives a positive PAS reaction indicating extracellular proteinaceous material. PAP is now rarely confirmed by surgical lung biopsy. WLL is still the first-line treatment, with an inhaled GM-CSF as second-line treatment. Inhalation has been found to be better than subcutaneous injections. Other treatments, such as rituximab or plasmapheresis, seem to be less efficient or ineffective. The main complications of PAP are due to infections by standard pathogens (Streptococcus, Haemophilus and Enterobacteria) or opportunistic pathogens such as mycobacteria, Nocardia, Actinomyces, Aspergillus or Cryptococcus. The clinical course of PAP is unpredictable and spontaneous improvement can occur. The 5-year actuarial survival rate is 95%.
Fichier principal
Vignette du fichier
Jouneau et al-2020-Pulmonary Alveolar Proteinosis.pdf (3.42 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-02735851 , version 1 (18-06-2020)



Stéphane Jouneau, Cedric Menard, Mathieu Lederlin. Pulmonary alveolar proteinosis. Respirology, 2020, 25 (8), pp.816-826. ⟨10.1111/resp.13831⟩. ⟨hal-02735851⟩
77 View
724 Download



Gmail Facebook Twitter LinkedIn More